PetMedix Ltd

PetMedix is elevating expectations in pet care by developing unprecedented therapeutic options for dogs and cats. Founded in 2018, PetMedix brings the leading edge of human biotechnology to the animal health arena with its breakthrough murine transgenic antibody platform. Its diverse group of 50 world-class scientists, as well as a board of investors spanning North America, Europe and Asia, give PetMedix international depth and global reach. With the announcement of collaborations with Zoetis and Boehringer Ingelheim and an oversubscribed series B financing round, the stage is set for PetMedix to transform pet health and welfare the world over.

Elevating Expectations in Pet Care

Stay up to date with PetMedix Ltd

Login or create a free user account to follow this company and see updates on your dashboard.

Create account